Innovative Tools for Molecular and Cell Biology

Innovative Tools for Molecular and Cell Biology

Products

Epstein-Barr Virus - EBV Assay Kits

ELISA-VIDITEST anti-EBV and IF-VIDITEST anti-EBV Kits

ELISA-VIDITEST anti-EBV

ELISA-VIDITEST anti-EBV

Description

  • ELISA-VIDITEST anti-EBV and IF-VIDTEST anti-EBV kits are intended for the diagnosis of EBV-associated diseases, i.e. infectious mononucleosis, chronic active EBV infection, EBV-related lymphoproliferative disorders and nasopharyngeal carcinoma. The tests can also contribute to laboratory examination of immune deficiency syndromes, chronic fatigue syndrome and other conditions when reactivation of latent EBV infection is common.

  • Markers of EBV infection:
    1. Viral capsid antigen – VCA: structural protein or protein complex, the compound of the viral capsid
    2. EB-viral nuclear antigen 1 – EBNA-1: nonstructural nuclear protein, present in latently infected cells
    3. Early antigen – EA: nonstructural protein or protein complex, synthetized in early phase of viral replication cycle. Based on the structure and localization in the infected cells, two components of EA can be distinguished: EA-R (restricted) component is present in distinct regions of cytoplasm and methanol-sensitive EA-D (diffuse) component is dispersed both in the cytoplasm and in the nucleus.

  • Antibody response against VCA, EA and EBNA-1 in the course of EBV infection display different dynamics.
  • Different phases of EBV infection can be distinguished according to the characteristic pattern of IgG, IgM and IgA antibodies against VCA, EBNA-1 and/or EA.

Kits for the Detection of Antibodies to EBV Viral Capsid Antigen - VCA

Features

  • Complete panel of EBV serological markers can be examined in single dilution of serum sample
  • Qualitative screening or quantitative determination
  • Validated for serum and cerebrospinal fluid (CSF) samples
  • Supplied with software for intrathecal antibody synthesis calculation
  • ELISA-VIDITEST anti-VCA IgM contains RF sorbent for elimination of interfering IgG antibodies
  • High sensitivity and specificity confirmed in multi-laboratory testing
  • IF test available for confirmation of the results

Description

  • IgG antibodies have anamnestic character and persist in an infected individual for the whole life. Seroconversion can be detected in early acute phase of the primary infection. A significant increase in IgG anti-VCA antibody indicates reinfection or reactivation. Avidity determination enables differentiation between primary and past infection and reactivation. IgM and IgA antibody response is typical for an active infection. High levels of IgM anti-VCA are usually present in acute and convalescent phase of infectious mononucleosis (IM), while in EBV reactivation IgM response is low and often undetectable and IgA response is more pronounced. After recovery, both IgM and IgA may persist for several weeks or months.

Overview on VCA assays

ELISA-VIDITEST RUO
Order # Product Method Evaluation No. of tests Sample Sensitivity/Specificity
ODZ-054 anti-VCA EBV IgG ELISA semiquant. 192 serum 98.1% / 97.1%
ODZ-084 anti-VCA EBV IgG (CSF)* ELISA quant. 96 serum, cerebrospinal fluid 98.1% / 97.1%
ODZ-175 anti-VCA EBV IgG and avidity IgG ELISA semiquant. 48 serum -
ODZ-005 anti-VCA EBV IgM ELISA semiquant. 96 serum 94.7% / 96.1%
ODZ-096 anti-VCA EBV IgA ELISA semiquant. 96 serum 85.3% (96%+)/ 100%
IF-VIDITEST RUO
ODZ-060 anti-VCA EBV IFA semiquant. 30x8 serum -

*determined from the positive IgM diagnosis patients data

Kits for the Detection of Antibodies to EBV Nuclear Antigen – EBNA-1

Anti-EBNA-1 assay kit

Features

  • Complete panel of EBV serological markers in single dilution of serum sample
  • Recombinant antigen guarantees high sensitivity and specificity (IgG det.)
  • No cross-reactive autoantibodies
  • Quantitative determination of IgG
  • High sensitivity/specificity according to diagnostic evaluation studies
  • ELISA-VIDITEST anti-EBNA-1 IgM contains highly specific synthetic peptide antigen

Description

  • In the acute phase of primary infection IgM antibody is present, while IgG antibody response is delayed. Absence of IgG anti-EBNA with concomitant presence of IgG and IgM anti-VCA is a diagnostic marker of infectious mononucleosis. Long term absence of IgG anti-EBNA-1 antibody may indicate immune deficiency.

Overview on EBNA-1 assays

ELISA-VIDITEST RUO
Order # Product Method Evaluation No. of tests Sample Sensitivity/Specificity
ODZ-015 anti-EBNA-1 EBV IgG – doublestrips ELISA semiquant. 96 serum 94.7% / 95.6%
ODZ-053 anti-EBNA-1 EBV IgG - break-away strips ELISA quant. 192 serum 94.7% / 96.5%
ODZ-001 anti-EBNA-1 EBV IgG ELISA quant. 96 serum 94.7% / 96.5%
ODZ-002 anti-EBNA-1 EBV IgM ELISA semiquant. 96 serum 95.5% / 95.5%

Kits for the Detection of Antibodies to EBV Early Antigen – EA

Features

  • Complete panel of EBV serological markers in a single dilution of serum sample
  • Quantitative determination or qualitative screening
  • IF assay enables differentiation of anti-EA(D) and anti-EA(R) antibody response and confirmation of the results in the alternative assay

Anti-EA assay kit

Description

  • Anti-EA IgG and IgM are supplemental markers of EBV activation (both primary infection and reactivation). High titers of anti-EA(D) are typical for late acute and convalescence phases of infectious mononucleosis, while anti-EA(R) is a more frequent marker of EBV reactivation. In chronic reactivation and chronic active EBV infections antibody response against both components can be found. High titers of IgG and IgA anti-EA(D) are observed in patients with nasopharyngeal carcinoma, the latter having prognostic significance. High levels of anti- EA(R) are characteristic for patients with EBV-associated Burkitt lymphoma.

Overview on EA assays

ELISA-VIDITEST RUO
Order # Product Method Evaluation No. of tests Sample Sensitivity/Specificity
OD-006 anti-EA(D) EBV IgG* ELISA semiquant. 96 serum 95.9% / 94.15%
OD-007 anti-EA(D) EBV IgM* ELISA semiquant. 96 serum -
IF-VIDITEST RUO
ODZ-057 anti-EA EBV IgG IFA IFA semiquant. 20x8 serum -
ODZ-058 anti-EA(D) EBV IgG IFA semiquant. 10x8 serum -

*determined from the positive IgM diagnosis patients data

ORDER INFORMATION

  • For shipping and storage information please click on Order#.
Order# Description Amount Price Data Sheet
ODZ-084 anti-VCA EBV IgG (CSF) 96 wells 153,00 PDF
ODZ-175 anti-VCA EBV IgG and IgG avidity 96 wells 147,60 PDF
ODZ-005 anti-VCA EBV IgM 96 wells 163,00 PDF
ODZ-096 anti VCA EBV IgA 96 wells 122,00 PDF
ODZ-060 anti-VCA EBV 240 wells 204,60 PDF
ODZ-015 anti-EBNA-1 EBV IgG, doublestrip 96 wells 91,00 PDF
ODZ-001 anti-EBNA-1 EBV IgG 96 wells 132,00 PDF
ODZ-002 anti-EBNA-1 EBV IgM 96 wells 142,00 PDF
ODZ-006 anti-EA (D) EBV IgG 96 wells 142,80 PDF
ODZ-007 anti-EA (D) EBV IgM 96 wells 142,80 PDF
ODZ-057 anti-EA EBV IgG 160 wells 160,60 PDF
ODZ-058 anti-EA (D) EBV IgG 80 wells 85,80 PDF
  • All prices are in EURO excl. VAT and shipping. Only available in selected countries.